Literature DB >> 12974478

Cancer vaccines: between the idea and the reality.

Olivera J Finn1.   

Abstract

Whether vaccines are designed to prepare the immune system for the encounter with a pathogen or with cancer, certain common challenges need to be faced, such as what antigen and what adjuvant to use, what type of immune response to generate and how to make it long lasting. Cancer, additionally, presents several unique hurdles. Cancer vaccines must overcome immune suppression exerted by the tumour, by previous therapy or by the effects of advanced age of the patient. If used for cancer prevention, vaccines must elicit effective long-term memory without the potential of causing autoimmunity. This article addresses the common and the unique challenges to cancer vaccines and the progress that has been made in meeting them. Considering how refractory cancer has been to standard therapy, efforts to achieve immune control of this disease are well justified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974478     DOI: 10.1038/nri1150

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  172 in total

1.  Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.

Authors:  Qian Qin; Zhaojun Yin; Philip Bentley; Xuefei Huang
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 2.  Nanoparticle systems for cancer vaccine.

Authors:  Ru Wen; Afoma C Umeano; Yi Kou; Jian Xu; Ammad Ahmad Farooqi
Journal:  Nanomedicine (Lond)       Date:  2019-02-26       Impact factor: 5.307

3.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

4.  Crosstalk between PKA and Epac regulates the phenotypic maturation and function of human dendritic cells.

Authors:  Jone Garay; June A D'Angelo; YongKeun Park; Christopher M Summa; Martha L Aiken; Eric Morales; Kamran Badizadegan; Edda Fiebiger; Bonny L Dickinson
Journal:  J Immunol       Date:  2010-08-20       Impact factor: 5.422

Review 5.  Hydrogels and scaffolds for immunomodulation.

Authors:  Ankur Singh; Nicholas A Peppas
Journal:  Adv Mater       Date:  2014-08-25       Impact factor: 30.849

Review 6.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  The use of signal peptide domains as vaccine candidates.

Authors:  Riva Kovjazin; Lior Carmon
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

9.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Authors:  Lili Yang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

Review 10.  Clustered carbohydrates in synthetic vaccines.

Authors:  Francesco Peri
Journal:  Chem Soc Rev       Date:  2012-12-18       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.